Get the Stockscreener App
108.53
0.65%
0.70
Incyte Corp stock is traded at $108.53, with a volume of 1.49M.
It is up +0.65% in the last 24 hours and up +9.48% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
See More
Previous Close:
$107.83
Open:
$107.83
24h Volume:
1.49M
Relative Volume:
0.95
Market Cap:
$21.68B
Revenue:
$5.36B
Net Income/Loss:
$1.43B
P/E Ratio:
15.35
EPS:
7.0718
Net Cash Flow:
$1.42B
1W Performance:
+6.01%
1M Performance:
+9.48%
6M Performance:
+13.75%
1Y Performance:
+56.79%
1-Day Range:
$106.53
$109.64
1-Week Range:
$98.78
$110.34
52-Week Range:
$66.74
$112.29
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
108.53 | 21.68B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Feb-05-26 | Initiated | H.C. Wainwright | Buy |
| Jan-20-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-08-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Rx Rundown: Incyte, Parabilis Medicines, Pfizer and more - Medical Marketing and Media
Incyte Stock (US45337C1027): Quarterly trends and sector context for US investors - AD HOC NEWS
Incyte Buys Vega To Add Late Stage Von Willebrand Disease Opportunity - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings - Investor's Business Daily
Incyte Corporation $INCY Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Incyte bolsters haematology portfolio in $2bn Vega buyout - MSN
Incyte Buyout Bet: The $2 Billion Move Investors Can’t Ignore! - Smartkarma
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Incyte to Acquire Vega Therapeutics from Star Therapeutics for Up to $2 Billion - Global Legal Chronicle
Why Incyte (INCY) Stock Is Up Today - Yahoo Finance
Incyte (INCY) director Jacqualyn Fouse awarded RSUs and 6,111 stock options - Stock Titan
H.C. Wainwright raises Incyte stock price target to $140 on Vega deal - Investing.com
Incyte to buy Vega Therapeutics in hematology deal worth up to $2B - MSN
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B - Yahoo! Finance Canada
INCY Maintains Rating by HC Wainwright & Co. -- Price Target Rai - GuruFocus
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster PotentialIncyte (NASDAQ:INCY - Benzinga
HC Wainwright Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Incyte to acquire blood disorder drug candidate for $2B - Delaware Business Times
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition - Investing.com
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition By Investing.com - Investing.com UK
Incyte Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Natixis Advisors LLC Purchases 10,795 Shares of Incyte Corporation $INCY - MarketBeat
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
Incyte Corporation (INCY) Announces Acquisition of Vega Therapeu - GuruFocus
Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff - MSN
Goodwin, Fenwick Guide Incyte-Vega Deal Worth Up To $2B - Law360
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Three Bay Area biotech startups ink big-company deals potentially totaling $5 billion - The Business Journals
Oppenheimer raises Incyte stock price target on Vega acquisition By Investing.com - Investing.com Australia
Oppenheimer raises Incyte stock price target on Vega acquisition - Investing.com India
Incyte To Acquire Vega Therapeutics For Up To $2 Billion To Expand Hematology Portfolio Into Bleeding Disorders - Pulse 2.0
Incyte (INCY) to Acquire Vega Therapeutics for $1.25B - GuruFocus
Incyte to acquire Vega Therapeutics in deal valued at up to $2B - The Business Journals
Incyte to acquire Star subsidiary Vega Therapeutics - The Pharma Letter
Incyte acquires Vega Therapeutics in $1.25 billion deal - grafa.com
Incyte Acquires Vega Therapeutics for $2 Billion, Expanding Hematology Portfolio with Phase 3 Bleeding Disorder Drug VGA039 - Minichart
Incyte to Acquire Vega Therapeutics in Up to $2 Billion Hematology Expansion - citybiz
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders - BioSpace
Incyte Study Shows Lymphoma Regimen Extends Progression-Free Survival - MyChesCo
Incyte makes Vega deal official, paying $1.25B upfront for bleeding disorder biotech - FirstWord Pharma
Incyte to buy company in late stages of development of bleeding control drug - Delaware Business Now
Incyte to buy blood disorder drug in possibly $2B deal - Yahoo Finance
Incyte to acquire Vega Therapeutics for $1.25B, up to $2.0B with milestones; VGA039 Phase 3 asset - TradingView
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary - Yahoo Finance
Savant Capital LLC Cuts Stake in Incyte Corporation $INCY - MarketBeat
BRIEF—Incyte eyeing acquisition of Star Therapeutics - The Pharma Letter
Incyte Corp. (INCY) Nears $2 Billion Acquisition of Star Therape - GuruFocus
Incyte Corp. (INCY) Nears $2 Billion Acquisition of Star Therapeutics - GuruFocus
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT (INCY:NASDAQ) - Seeking Alpha
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 10,000 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):